CATH.a細胞
生長狀態： 混合型生長
器官來源： 大腦
數量： 大量
ATCC Number： CRL-11179?
細胞類型： 其他細胞類型
運輸方式： 凍存運輸
是否是腫瘤細胞： 0
物種來源： 小鼠
Designations: CATH.a
CATH.a細胞Depositors: Trustees of Tufts University
Biosafety Level: 2 [Cells contain SV-40 viral DNA sequences ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: mixed: adherent and suspension
Organism: Mus musculus
Morphology:
Source: Organ: brain
Cell Type: neuron;
Cellular Products: dopamine; norepinephrine; synaptophysin
Permits/Forms: CATH.a細胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Comments: The CATH.a cell line was established from cultures of a tumor that arose in the brain of a transgenic mouse.
The transgene contain the SV40 T antigen coding sequence linked to a 783 bp portion of the rat tyrosine hydroxylase gene.
The cells express tyrosine hydroxylase and dopamine beta-hydroxylase, and contain neurofilaments.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 88%; horse serum, 8%; fetal bovine serum, 4%
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol: CATH.a細胞Cultures can be maintained by transferring floating cells to additional flasks.Subculture attached cells using 0.12% trypsin without EDTA.Remove Trypsin by neutralization and centrifugation.
Subcultivation Ratio: A subcultivation ratio of 1:4 is recommended
Preservation: Freeze medium: complete growth medium, 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
CATH.a細胞References: 22129: Chikaraishi DM. Expression of a target gene in transgenic mammals with 5' flanking sequences of the rat tyrosine hydroxylase gene. US Patent 5,591,626 dated Jan 7 1997
